ArticleInvestigative ophthalmology & visual science2026
Aflibercept and Faricimab Equipotently Restore Endothelial Barrier Function.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To study the biological effects of aflibercept and faricimab on vascular endothelial growth factor (VEGF)-A165-induced vascular permeability in an in vitro head-to-head comparison using human-derived endothelial cells. Methods: This in vitro study used a human umbilical vein endothelial cell (HUVEC)-based model, in which cells were exposed to VEGF-A165, followed by the addition of aflibercept (1.7 nM) or faricimab (2.0 nM) either simultaneously (preventive) or 24 hours later (therapeutic/rescue). Cell-layer permeability was measured on the xCELLigence platform, global transcriptomic changes by RNA sequencing, and VEGF-A165-induced release of angiogenesis-related proteins by electrochemiluminescence immunoassay. Results: Concurrent addition of aflibercept or faricimab prevented VEGF-A165-triggered increase of HUVEC cell-layer permeability (P = 0.0005). In the therapeutic/rescue setting, either drug temporally improved the cell-layer integrity (P = 0.0001). Aflibercept was non-inferior to faricimab in both the preventive (P < 0.0001) and therapeutic/rescue (P < 0.0001) settings. Aflibercept and faricimab comparably downregulated VEGF-A165-induced angiogenesis-related genes. Aflibercept and faricimab equipotently suppressed or reversed VEGF-A165 upregulation of ANGPT2 gene expression and angiopoietin-2 (ANG2) protein in culture supernatant. VEGF-A165-driven TEK gene expression and soluble Tie2 increase in culture supernatant was reversed with aflibercept and faricimab in both settings. Conclusions: In this in vitro model of VEGF-A165-driven vascular permeability, additional blockade of ANG2 with faricimab did not improve endothelial barrier integrity beyond VEGF-A165 blockade alone with aflibercept, despite significant upregulation of ANG2 expression after VEGF-A165 stimulation. Aflibercept and faricimab were comparable in maintaining or restoring endothelial barrier function and thereby vascular integrity, mainly attributable to inhibition of VEGF-A165 binding to its receptor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.